Welcome to our dedicated page for Avanos Medical news (Ticker: AVNS), a resource for investors and traders seeking the latest updates and insights on Avanos Medical stock.
Avanos Medical, Inc. reports developments as a medical technology company that develops, manufactures and markets medical device solutions for Specialty Nutrition Systems and Pain Management and Recovery. Its news commonly covers operating results, segment growth, enteral feeding products, non-opioid surgical pain and recovery products, infusion pumps, radiofrequency ablation solutions and cryo-pneumatic compression systems.
Company updates also include Medicare payment and regulatory reimbursement developments for ON-Q, AmbIT and Game Ready, collaborations for outpatient and interventional pain workflows, investor conference presentations, cost and transformation initiatives, and governance matters such as board nominations and shareholder agreements.
Avanos Medical, Inc. (NYSE: AVNS) will have CEO Joe Woody present at the Virtual KeyBanc Life Sciences & MedTech Investor Forum on March 23, 2021, at approximately 2 p.m. ET. A live webcast of the presentation can be accessed in the Investors section of Avanos Medical's website, where it will also be archived. Avanos Medical is dedicated to enhancing patient care and reducing opioid use through innovative medical devices.
Avanos Medical (NYSE: AVNS) announced that Michael Greiner, senior vice president and chief financial officer, will present at the Virtual Raymond James 42nd Annual Institutional Investors Conference on March 1 at approximately 3:50 p.m., ET. A live webcast of the presentation will be available on Avanos' Investors section and archived on their website.
Avanos Medical reported Q4 2020 net sales of $185 million, down 3% year-over-year, while full-year sales rose 3% to $715 million. The Q4 net loss was $47 million, compared to a loss of $6 million last year. Adjusted net income for the quarter was $13 million, down from $16 million a year ago. The company implemented a restructuring program projected to yield $7 million in annual savings. Notably, the restructuring led to an overall charge of $25-$30 million. Despite pandemic challenges, the company aims for growth and margin improvement in 2021.
Avanos Medical (NYSE: AVNS) will hold a conference call on Feb. 18, 2021, at 9 a.m. ET, to discuss its fourth quarter and full-year 2020 financial results. A news release detailing these results will be issued before market open that day. The call will be hosted by CEO Joe Woody and CFO Michael Greiner. Investors can join the call by dialing 877-240-5772 or access a live webcast via the Avanos Medical website. A replay will be available starting Feb. 18 at noon ET for one week.
Avanos Medical (NYSE: AVNS) will have CEO Joe Woody present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at approximately 2 p.m. ET. This presentation will be available via a live webcast, including a Q&A session, accessible through the Investors section of Avanos Medical's website and will be archived for later viewing. The company focuses on innovative healthcare solutions aimed at reducing opioid use and improving patient recovery.
Avanos Medical, Inc. (NYSE: AVNS) will present at two virtual investor conferences in November 2020. The Stifel 2020 Virtual Healthcare Conference will take place on Nov. 18 at 10 a.m. ET, featuring CEO Joe Woody. The Stephens Annual Investment Conference is scheduled for Nov. 19 at 8 a.m. ET, with CFO Michael Greiner speaking. Investors can access webcasts of both presentations on the Investors section of the Avanos Medical website. The company focuses on breakthrough medical device solutions to improve patient quality of life.
Avanos Medical reported third quarter 2020 net sales of $186 million, an 8% increase year-over-year. The company achieved a net income of $19 million, rebounding from a loss of $12 million last year. Despite challenges from the pandemic, demand for Respiratory Health products drove growth. Adjusted EBITDA was $24 million, slightly down from $25 million a year ago. The company continues to manage expenses effectively while investing in growth. However, it anticipates ongoing uncertainty due to COVID-19's impact on elective procedures.
Avanos Medical, Inc. (NYSE: AVNS) will hold a conference call on November 3, 2020, at 9 a.m. ET to discuss its third-quarter 2020 financial results. A news release detailing the financial results will be issued prior to the market opening on the same day. The call, hosted by CEO Joe Woody and CFO Michael Greiner, will be accessible via a live webcast on the Avanos Medical website. Replays will be available post-call on the same platform for one week.
Avanos Medical, Inc. (NYSE: AVNS) has appointed Michelle Scharfenberg as its new senior vice president & chief ethics and compliance officer, effective immediately. With over 20 years of experience in healthcare law and compliance, Scharfenberg is set to lead the company’s Compliance & Ethics program, aligning it with the company’s commitment to ethical operations. Previously, she was vice president and chief compliance officer at Cantel Medical Corporation. CEO Joe Woody emphasized the importance of this role in maintaining Avanos's reputation in the global medical device market.
Avanos Medical, Inc. (NYSE: AVNS) will present at two virtual investor conferences in September 2020. The first, the Morgan Stanley 18th Annual Global Healthcare Conference, is scheduled for Mon., Sept. 14 at 5 p.m. ET, featuring CEO Joe Woody. The second, the Cantor Virtual Global Healthcare Conference, will take place on Thurs., Sept. 17 at 8 a.m. ET, with CFO Michael Greiner speaking. Webcasts of the presentations will be accessible on the Avanos Medical website's Investors section, and both sessions will be archived for later viewing.